ProCE Banner Activity


Critical Conversations in Advanced RCC: Guidance on Immunotherapy and Immunotherapy-Based Combinations


Watch this on-demand webcast from a June 2023 roundtable webinar featuring Eric Jonasch, MD; Brian Rini, MD, FASCO; and Tian Zhang, MD, MHS, on current guidance and emerging strategies for treating patients with advanced RCC.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 22, 2023

Expiration: June 21, 2024

No longer available for credit.



Eric Jonasch

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Brian Rini

Brian Rini, MD, FASCO

Chief of Clinical Trials 
Division of Hematology/Oncology 
Vanderbilt University Medical Center
Nashville, Tennesee 

Tian Zhang

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for urologic and medical oncologists, urologists, and other multidisciplinary care team members who treat patients with advanced/metastatic RCC.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance, practice-changing data, and expert recommendations on immunotherapy and immunotherapy-based combinations in advanced/metastatic RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate treatment plans in the frontline setting using available clinical evidence and patient-, disease-, and treatment-related factors in patients with advanced/metastatic RCC

  • Appraise clinical trial data evaluating the use of anti‒PD-1/PD-L1 antibody/multikinase inhibitor and anti‒PD-1/anti‒CTLA-4/multikinase inhibitor combination therapy in patients with advanced/metastatic RCC

  • Review expert-recommended therapeutic sequencing of systemic therapies for patients with advanced/metastatic RCC that has progressed on first-line treatment, incorporating immunotherapeutic agents and other therapeutic strategies

  • Integrate best practices to recognize, mitigate, and manage the unique suite of adverse events associated with immunotherapy and immunotherapy-based combination treatment approaches for patients with advanced/metastatic RCC


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Eric Jonasch, MD: consultant/advisor/speaker: Aveo, Aravive, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, Nikang, Takeda; researcher: Arrowhead, Corvus, Merck, Nikang

Brian Rini, MD, FASCO: consultant/advisor/speaker: Alkermes, Aravive, Arrowhead, Athenex, Aveo, Bristol Myers Squibb, Corvus, Debiopharm, Eisai, EUSA, GNE/Roche, HiberCell, Merck, Nikang Therapeutics, Pfizer, Surface Oncology, Synthorx; researcher (paid to institution): ADC Therapeutics, Adela, Aravive, Arcus, Arrowhead, AstraZeneca, AVEO, Bristol Myers Squibb, Daiichi Sankyo, Dracen, Dragonfly, Exelixis, Genentech, Gilead, HiberCell, Incyte, Janssen, Merck, Pfizer, Pionyr, POINT Biopharma, Stata Oncology, Surface Oncology, Tempus, VasGene; individual publicly traded stocks and stock options: PTC Therapeutics.

Tian Zhang, MD, MHS: consultant/advisor/speaker: Amgen, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, Pfizer, PlatformQ, QED Therapeutics, Sanofi-Aventis, Seagen, Vaniam Group; researcher (paid to institution): AbbVie/Stemcentrx, AstraZeneca, Janssen, Lilly, Merck, Merrimack, Mirati Therapeutics, Novartis, Pfizer, Regeneron, Tempus; data and safety monitoring board: Aravive.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 22, 2023, through June 21, 2024:
1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the post-test questions and evaluation questions online 
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material  for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.